Baidu
map

Oncogenesis:CUL4B能够通过与SOX4形成正反馈循环促进前列腺癌恶化

2019-03-29 AlexYang MedSci原创

怎样从恶性疾病中区分无痛性疾病在前列腺癌(PCa)的治疗中仍旧是一个巨大的挑战。Cullin 4B (CUL4B)是一种支架蛋白并且在多种人类恶性肿瘤中表现出了致瘤活性。最近,有研究人员利用PCa组织样本、细胞系和异种种植模型确定了是否CUL4B能够导致PCa恶化和转移。研究发现,CUL4B的表达与PCa的恶化过程相关。CUL4B的表达能够促进PCa细胞的增殖、上皮间质转化和PCa细胞的转移,而C

怎样从恶性疾病中区分无痛性疾病在前列腺癌(PCa)的治疗中仍旧是一个巨大的挑战。Cullin 4B (CUL4B)是一种支架蛋白并且在多种人类恶性肿瘤中表现出了致瘤活性。最近,有研究人员利用PCa组织样本、细胞系和异种种植模型确定了是否CUL4B能够导致PCa恶化和转移。

研究发现,CUL4B的表达与PCa的恶化过程相关。CUL4B的表达能够促进PCa细胞的增殖、上皮间质转化和PCa细胞的转移,而CUL4B下调能够抑制上述作用。同时,CUL4B能够通过miR-204的表观遗传沉默来正调控PCa中的一个关键调控子SOX4。相反,SOX4能够通过转录激活来上调CUL4B的表达,从而完成一个正反馈通路。临床上,CUL4B+/SOX4+能够定义不良预后的PCa患者。生物信息学分析进一步阐释了Wnt/ß-连环蛋白激活特性在CUL4B+/SOX4+患者亚群中富集。另外,Wnt抑制剂能够显著的减弱体内和体外试验中CUL4B的致瘤能力。

最后,研究人员指出,他们的研究阐明了CUL4B通过与SOX4互作形成正反馈调控途径,是恶性PCa的一个关键调控因。该调控途径可能在PCa的恶化过程中具有重要的作用。

原始出处:

Mei Qi, Jing Hu, Yanyi Cui et al. CUL4B promotes prostate cancer progression by forming positive feedback loop with SOX4. Oncogenesis. 14 Mar 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2049167, encodeId=c2c3204916e93, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Sep 04 16:05:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558149, encodeId=a77c1558149e8, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sun Mar 31 05:05:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588365, encodeId=bc781588365d4, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Sun Mar 31 05:05:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040428, encodeId=8cdc104042847, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Mar 29 17:05:00 CST 2019, time=2019-03-29, status=1, ipAttribution=)]
    2019-09-04 cy0324
  2. [GetPortalCommentsPageByObjectIdResponse(id=2049167, encodeId=c2c3204916e93, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Sep 04 16:05:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558149, encodeId=a77c1558149e8, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sun Mar 31 05:05:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588365, encodeId=bc781588365d4, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Sun Mar 31 05:05:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040428, encodeId=8cdc104042847, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Mar 29 17:05:00 CST 2019, time=2019-03-29, status=1, ipAttribution=)]
    2019-03-31 zsyan
  3. [GetPortalCommentsPageByObjectIdResponse(id=2049167, encodeId=c2c3204916e93, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Sep 04 16:05:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558149, encodeId=a77c1558149e8, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sun Mar 31 05:05:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588365, encodeId=bc781588365d4, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Sun Mar 31 05:05:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040428, encodeId=8cdc104042847, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Mar 29 17:05:00 CST 2019, time=2019-03-29, status=1, ipAttribution=)]
    2019-03-31 skhzy
  4. [GetPortalCommentsPageByObjectIdResponse(id=2049167, encodeId=c2c3204916e93, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Sep 04 16:05:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558149, encodeId=a77c1558149e8, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sun Mar 31 05:05:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588365, encodeId=bc781588365d4, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Sun Mar 31 05:05:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040428, encodeId=8cdc104042847, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Mar 29 17:05:00 CST 2019, time=2019-03-29, status=1, ipAttribution=)]
    2019-03-29 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

NCCN临床实践指南:前列腺癌(2019.V1)

2019年3月,美国国家综合癌症网络(NCCN)发布了前列腺癌指南2019年第1版,指南主要内容涉及: 指南更新摘要 初始前列腺癌诊断 非常低风险:初始治疗、辅助治疗 低风险:初始治疗、辅助治疗 中间风险:初始治疗、辅助治疗 高风险,极高风险:初始治疗、辅助治疗 检测,复发 前列腺切除术失败 放射治疗复发 系统治疗 M1 CRPC随后系统治疗 生存寿命评估原则 影像检查原则 积极监测和观察原则 放

Sci Rep:雄激素受体基因变异在循环无细胞DNA中作为生物标记在去势抵抗性前列腺癌中的应用研究

去势抵抗性前列腺癌(CRPC)的治疗范围迅速扩大。因此,当前需要开发非侵入性的生物标记来指导治疗。最近,有研究人员在血浆循环无细胞DNA(cfDNA)中建立了一种高敏感的方法来分析雄激素受体基因(AR)拷贝数(CN)和变异,并且评估CRPC患者的AR状态情况。在VCaP细胞系(AR扩增后)基因组DNA(gDNA)稀释到1%时,可以通过数字PCR(dPCR)来检测AR的扩增情况。在LNCaP细胞系(

Prostate Cancer P D:SPINK1表达在非裔美国人前列腺中富集并且与术后免疫浸润或者肿瘤结果无关

SPINK1分子亚型在非裔美国人(AA)前列腺恶性肿瘤(PCa)中要比欧裔美国人(EA)更为常见。有研究表明SPINK1表达与更富侵略性的疾病相关。然而,先前患者群体的大小、跟踪调查情况和种族差异限制了对SPINK1在AA男性中表达的理解。最近,有研究人员确定了根治性前列腺切除术(RP)后SPINK1亚型与种族和肿瘤结果的相关性。研究包括了经历了RP的186名AA和206名EA男性,并根据病理等级

盘点:前列腺癌与治疗进展盘点

【1】Oncogene:Karyopherin β1的抑制能够抑制前列腺癌的生长 前列腺癌(PCa)的起始和进展需要大量的致瘤信号途径的激活。在细胞转化期间,致瘤因子在核质转运的过程受Karyopherin蛋白的调节。然而,核转运蛋白在PCa进展中的作用还没有很好的解释。最近,有研究人员报道了一个关键的Karyopherin β亚基-KPNB1,在晚期前列腺癌中高度表达。进一步的研究

盘点:前列腺癌与相关机制

【1】Nucleic Acids Res:揭示长链非编码RNA PCAT1促进去势抵抗性前列腺癌进展的新机制 http://academic.oup.com/nar/advance-article/doi/10.1093/nar/gkz108/5324447在PTEN缺失的前列腺癌中,AKT信号通路的激活依赖于雄激素受体信号通路的抑制。HLPP/FKBP51/IKKα蛋白复合体在AKT和NF-

Prostate Cancer P D:MRI-US融合前列腺活检学习曲线鉴定分析

MRI-US融合前列腺活检在诊断前列腺癌中已经成为一种常见的步骤。考虑到融合活检的学习曲线,仍旧缺乏相关信息。最近,有研究人员研究了在该步骤中能够准确和有效进行时需要的经验量。研究人员前瞻性的搜集了MRI-US融合活检的患者数据,这些融合活检在2014年4月到2017年8月之间进行。研究人员利用2个参数来定义学习曲线,即效率和准确度。之后,他们利用图形和数学的方法来确定学习曲线。研究人员为完成了7

Baidu
map
Baidu
map
Baidu
map